COVID-19 vaccine supporters are fond of sneering at public figures who have called for the Food and Drug Administration to pull or at least re-evaluate the safety of the increasingly unpopular therapeutics, such as Health and Human Services secretary nominee Robert F. Kennedy Jr., cardiologist Peter McCullough and Florida Surgeon General Joseph Ladapo.
Read More
A jury awarded a record $12.6 million to woman fired from Blue Cross Blue Shield Michigan for not getting the COVID-19 vaccine.
Read More
A year after promoting passports for the COVID-19 vaccines he helped fund as a way to reopen the global economy, philanthropist Bill Gates complained about their lackluster performance against infection and transmission starting with the Delta variant of SARS-CoV-2. He even called Omicron “a type of vaccine” whose natural immunity could protect unvaccinated groups.
Read More
Late last month, the U.S. Food and Drug Administration (FDA) approved a monkeypox vaccine that is known to “shed from the vaccination site” and cause heart inflammation in about 1 in every 175 persons.
ACAM2000, made by Emergent BioSolutions, was developed to prevent monkeypox disease in individuals determined to be at high risk for mpox infection. But according to the FDA’s own medication guide for the product, the risks of the vaccine appear to outweigh the benefits.
Read More
The earliest recipients of newly authorized COVID-19 vaccines, including healthcare workers, wrote in tens of thousands of adverse events related to the heart, ears, reproductive system and other conditions not listed as checkboxes in a federal active monitoring smartphone app.
The Centers for Disease Control and Prevention in the past two months turned over 780,000 “free text” entries from V-safe, the agency’s vaccine-safety monitoring system, under a January order by U.S. District Judge Matthew Kacsmaryk in a Freedom of Information Act lawsuit by Freedom Coalition of Doctors for Choice.
Read More
Finances at the vaccine manufacturer Moderna began to fall almost as quickly as they had risen, as most Americans resisted getting yet another COVID booster shot. The pharmaceutical company, whose pioneering mRNA vaccine had turned it from small startup to biotech giant worth more than $100 billion in just a few years, reported a third-quarter loss last year of $3.6 billion, as most Americans refused to get another COVID booster shot.
In a September call aimed at shoring up investors, Moderna’s then-chief commercial officer, Arpa Garay, attributed some of the hesitancy pummeling Moderna’s numbers to uninformed vaccine skeptics. “Despite some misinformation,” Garay said, COVID-19 still drove significant hospitalizations. “It really is a vaccine that’s relevant across all age groups,” she insisted.
Read More